A
Menu
First published October 16, 2025 Application Aachen patent C – Chemistry & metallurgy

PROTAC COMPOUNDS

Espacenet Family 91274816

Abstract

The present invention relates to certain compounds of Formula (I) that function as a proteolysis targeting chimera (PROTAC) against CCR2; wherein X, L, E3, ring A, integer a, Y, ring B, integer b and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which CCR2 activity is implicated.

Inventors 3

  1. Laura H. Heitman Aachen author as filed: Heitman, Laura
  2. Daan van der Es Aachen author as filed: van der Es, Daan
  3. Khaled Essa Aachen author as filed: Essa, Khaled

Inventors are linked to an Aachen author when surname and first name match exactly one author.

Applicants

Cited papers 30 in the database

Non-patent literature as cited (45)
  • - JERRY MARCH: "Advanced Organic Chemistry", 2001, JOHN WILEY AND SONS, pages: 131 - 133
  • - L. W. DEADY, SYN. COMM., vol. 7, 1977, pages 509 - 514
  • - "Methods in Enzymology", vol. 42, 1985, ACADEMIC PRESS, pages: 309 - 396
  • - H. BUNDGAARD: "A Textbook of Drug Design and Development", article "Design and Application of Pro-drugs", pages: 113 - 191
  • - H. BUNDGAARD, ADVANCED DRUG DELIVERY REVIEWS, vol. 8, 1992, pages 1 - 38
  • - H. BUNDGAARD ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 77, 1988, pages 285
  • - N. KAKEYA ET AL., CHEM. PHARM. BULL., vol. 32, 1984, pages 692
  • - T. HIGUCHIV. STELLA: "Pro-Drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14
  • - "Bioreversible Carriers in Drug Design", 1987, PERGAMON PRESS
  • - J. MED. CHEM., vol. 47, 2004, pages 6658 - 6661
  • - STERN ET AL., CRITICAL REVIEWS IN ONCOLOGY/HAEMATOLOGY, vol. 54, 2005, pages 11 - 29
  • - BACON, K.BAGGIOLINI, M.BROXMEYER, H.HORUK, R.LINDLEY, I.MANTOVANI, A.MATSUSHIMA, K.MURPHY, P.NOMIYAMA, H.OPPENHEIM, J.: "Chemokine/Chemokine Receptor Nomenclature", CYTOKINE, vol. 21, no. 1, 2003, pages 48 - 49, Retrieved from the Internet <URL:https://doi.org/10.1016/S1043-4666(02)00493-3>
  • - YAMASAKI, R.LIU, L.LIN, J.RANSOHOFF, R. M.: "Role of CCR2 in Immunobiology and Neurobiology", CLIN EXP NEUROIMMUNOL, vol. 3, no. 1, 2012, pages 16 - 29, XP072399677, Retrieved from the Internet <URL:https://doi.org/10.1111/J.1759-1961.2011.00024.X> DOI: 10.1111/j.1759-1961.2011.00024.x
  • - CONNOR, S. J.PARASKEVOPOULOS, N.NEWMAN, R.CUAN, N.HAMPARTZOUMIAN, T.LLOYD, A. R.GRIMM, M. C.: "CCR2 Expressing CD4+ T Lymphocytes Are Preferentially Recruited to the Ileum in Crohn's Disease", GUT, vol. 53, no. 9, 2004, pages 1287, XP055057821, Retrieved from the Internet <URL:https://doi.org/10.1136/GUT.2003.028225> DOI: 10.1136/gut.2003.028225
  • - GEISSMANN, F.JUNG, S.LITTMAN, D. R.: "Blood Monocytes Consist of Two Principal Subsets with Distinct Migratory Properties", IMMUNITY, vol. 19, no. 1, 2003, pages 71 - 82, XP055234933, Retrieved from the Internet <URL:https://doi.org/10.1016/S1074-7613(03)00174-2> DOI: 10.1016/S1074-7613(03)00174-2
  • - YERRA, V. G.ADVANI, A.: "Role of CCR2-Positive Macrophages in Pathological Ventricular Remodelling", BIOMEDICINES, vol. 10, no. 3, 2022, pages 661, Retrieved from the Internet <URL:https://doi.org/10.3390/BIOMEDICINES10030661>
  • - ZHENG, Y.QIN, L.ZACARIAS, N. V. O.DE VRIES, H.HAN, G. W.GUSTAVSSON, M.DABROS, M.ZHAO, C.CHERNEY, R. J.CARTER, P.: "Structure of CC Chemokine Receptor 2 with Orthosteric and Allosteric Antagonists", NATURE, vol. 540, no. 7633, 2016, pages 458 - 461, XP037473962, Retrieved from the Internet <URL:https://doi.org/10.1038/nature20605> DOI: 10.1038/nature20605
  • - SHAO, Z.TAN, Y.SHEN, Q.HOU, L.YAO, B.QIN, J.XU, P.MAO, C.CHEN, L. N.ZHANG, H.: "Molecular Insights into Ligand Recognition and Activation of Chemokine Receptors CCR2 and CCR3", CELL DISCOVERY 2022, vol. 8, no. 1, 2022, pages 1 - 11, Retrieved from the Internet <URL:https://doi.org/10.1038/s41421-022-00403-4>
  • - LOYHER, P. L.ROCHEFORT, J.BAUDESSON DE CHANVILLE, C.HAMON, P.LESCAILLE, G.BERTOLUS, C.GUILLOT-DELOST, M.KRUMMEL, M. F.LEMOINE, F. : "CCR2 Influences T Regulatory Cell Migration to Tumors and Serves as a Biomarker of Cyclophosphamide Sensitivity", CANCER RES, vol. 76, no. 22, 2016, pages 6483 - 6494, Retrieved from the Internet <URL:https://doi.org/10.1158/0008-5472.CAN-16-0984>
  • - HAO, Q.VADGAMA, J. V.WANG, P.: "CCL2/CCR2 Signaling in Cancer Pathogenesis", CELL COMMUNICATION AND SIGNALING 2020, vol. 18, no. 1, 2020, pages 1 - 13, XP055938583, Retrieved from the Internet <URL:https://doi.org/10.1186/S12964-020-00589-8> DOI: 10.1186/s12964-020-00589-8
  • - O'CONNOR, T.BORSIG, L.HEIKENWALDER, M.: "CCL2-CCR2 Signaling in Disease Pathogenesis", ENDOCRINE, METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, vol. 15, no. 2, 2015, pages 105 - 118, Retrieved from the Internet <URL:https://doi.org/10.2174/1871530315666150316120920>
  • - NAHRENDORF, M.SWIRSKI, F. K.: "Cholesterol, CCR2, and Monocyte Phenotypes in Atherosclerosis", EUR HEART J, vol. 38, no. 20, 2017, pages 1594 - 1596, Retrieved from the Internet <URL:https://doi.org/10.1093/EURHEARTJ/EHX098>
  • - WU, X. B.JING, P. B.ZHANG, Z. J.CAO, D. L.GAO, M. H.JIANG, B. C.GAO, Y. J.: "Chemokine Receptor CCR2 Contributes to Neuropathic Pain and the Associated Depression via Increasing NR2B-Mediated Currents in Both D1 and D2 Dopamine Receptor-Containing Medium Spiny Neurons in the Nucleus Accumbens Shell", NEUROPSYCHOPHARMACOLOGY, vol. 43, no. 11, 2018, pages 2320 - 2330, XP036590121, Retrieved from the Internet <URL:https://doi.org/10.1038/S41386-018-0115-8> DOI: 10.1038/s41386-018-0115-8
  • - SHE, S.; WU, X.; ZHENG, D.; PEI, X.; MA, J.; SUN, Y.; ZHOU, J.; NONG, L.; GUO, C.; LV, P.; SONG, Q.; ZHENG, C.; LIANG, W.; HUANG, : "PSMP/MSMP Promotes Hepatic Fibrosis through CCR2 and Represents a Novel Therapeutic Target", J HEPATOL, vol. 72, no. 3, 2020, pages 506 - 518, XP086049256, Retrieved from the Internet <URL:https://doi.org/10.1016/J.JHEP.2019.09.033.> DOI: 10.1016/j.jhep.2019.09.033
  • - RANA, A. K.LI, Y.DANG, Q.YANG, F: "Monocytes in Rheumatoid Arthritis: Circulating Precursors of Macrophages and Osteoclasts and, Their Heterogeneity and Plasticity Role in RA Pathogenesis", INT IMMUNOPHARMACOL, vol. 65, 2018, pages 348 - 359, XP085545421, Retrieved from the Internet <URL:https://doi.org/10.1016/J.INTIMP.2018.10.016> DOI: 10.1016/j.intimp.2018.10.016
  • - CLINICALTRIALS.GOV, 22 November 2023 (2023-11-22), Retrieved from the Internet <URL:https://clinicaltrials.gov/search?cond=ccr2&aggFilters=studyType:int>
  • - ANSTEE, Q. M.NEUSCHWANDER-TETRI, B. A.WAI-SUN WONG, V.ABDELMALEK, M. F.RODRIGUEZ-ARAUJO, G.LANDGREN, H.PARK, G. S.BEDOSSA, P.ALKHO: "Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study", CLIN GASTROENTEROL HEPATOL, 2023, Retrieved from the Internet <URL:https://doi.org/10.1016/J.CGH.2023.04.003>
  • - HORUK, R.: "Chemokine Receptor Antagonists: Overcoming Developmental Hurdles", NATURE REVIEWS DRUG DISCOVERY, vol. 8, no. 1, 2009, pages 23 - 33, XP007909904, Retrieved from the Internet <URL:https://doi.org/10.1038/nrd2734>
  • - PIENTA, K. J.MACHIELS, J. P.SCHRIJVERS, D.ALEKSEEV, B.SHKOLNIK, M.CRABB, S. J.LI, S.SEETHARAM, S.PUCHALSKI, T. A.TAKIMOTO, C.: "Phase 2 Study of Carlumab (CNTO 888), a Human Monoclonal Antibody against CC-Chemokine Ligand 2 (CCL2), in Metastatic Castration-Resistant Prostate Cancer", INVEST NEW DRUGS, vol. 31, no. 3, 2013, pages 760 - 768, Retrieved from the Internet <URL:https://doi.org/10.1007/S10637-012-9869-8>
  • - RUFFILLI, C.; ROTH, S.; RODRIGO, M.; BOYD, H.; ZELCER, N.; MOREAU, K.: "Pharmacology and Translational Science", 14 October 2022, AMERICAN CHEMICAL SOCIETY, article "Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation Pharmacology and Translational Science", pages: 849 - 858
  • - TENG, M.GRAY, N. S.: "The Rise of Degrader Drugs", CELL CHEM BIOL, vol. 30, no. 8, 2023, pages 864 - 878, XP087375700, Retrieved from the Internet <URL:https://doi.org/10.1016/J.CHEMBIOL.2023.06.020> DOI: 10.1016/j.chembiol.2023.06.020
  • - WENG, G.CAI, X.CAO, D.DU, H.SHEN, C.DENG, Y.HE, Q.YANG, B.LI, D.HOU, T.: "PROTAC-DB 2.0: An Updated Database of PROTACs", NUCLEIC ACIDS RES, vol. 51, no. D1, 2023, pages 1367 - 1372, Retrieved from the Internet <URL:https://doi.org/10.1093/nar/gkac946>
  • - SRIRAM, K.; INSEL, P. A. G: "Protein-Coupled Receptors as Targets for Approved Drugs:How Many Targets and How Many Drugs?", MOL PHARMACOL, vol. 93, no. 4, 2018, pages 251 - 258, Retrieved from the Internet <URL:https://doi.org/10.1124/MOL.117.111062/-/DC1.>
  • - HUBER, M. E.TOY, L.SCHMIDT, M. F.VOGT, H.BUDZINSKI, J.WIEFHOFF, M. F. J.MERTEN, N.KOSTENIS, E.WEIKERT, D.SCHIEDEL, M.: "A Chemical Biology Toolbox Targeting the Intracellular Binding Site of CCR9: Fluorescent Ligands, New Drug Leads and PROTACs", ANGEWANDTE CHEMIE - INTERNATIONAL EDITION 2022, vol. 61, no. 12, Retrieved from the Internet <URL:https://doi.org/10.1002/anie.202116782>
  • - LI, Z.LIN, Y.SONG, H.QIN, X.YU, Z.ZHANG, Z.DONG, G.LI, X.SHI, X.DU, L.: "First Small-Molecule PROTACs for G Protein-Coupled Receptors: Inducing A1A-Adrenergic Receptor Degradation", ACTA PHARM SIN B, vol. 10, no. 9, 6 January 1969 (1969-01-06), Retrieved from the Internet <URL:https://doi.org/10.1016/J.APSB.2020.01.014>
  • - LU, A. S.ROUHIMOGHADAM, M.ARNATT, C. K.FILARDO, E. J.SALEM, A. K.: "Proteolytic Targeting Chimeras with Specificity for Plasma Membrane and Intracellular Estrogen Receptors", MOL PHARM, vol. 18, no. 3, 2021, pages 1455 - 1469, XP055823915, Retrieved from the Internet <URL:https://doi.org/10.1021/ACS.MOLPHARMACEUT.1C00018> DOI: 10.1021/acs.molpharmaceut.1c00018
  • - ORTIZ ZACARIAS, N. V.CHAHAL, K. K.ŠIMKOVÁ, T.VAN DER HORST, C.ZHENG, Y.INOUE, A.THEUNISSEN, E.MALLEE, L.VAN DER ES, D.LOUVEL, J.: "Design and Characterization of an Intracellular Covalent Ligand for CC Chemokine Receptor 2", J MED CHEM, vol. 64, no. 5, 2021, pages 2608 - 2621, XP055888700, Retrieved from the Internet <URL:https://doi.org/10.1021/ACS.JMEDCHEM.OC01137/SUPPL_FILE/JMOC01137_SI_004.PDB> DOI: 10.1021/acs.jmedchem.0c01137
  • - ROGER, J.POŽGAN, F.DOUCET, H.: "Ligand-Free Palladium-Catalyzed Direct Arylation of Thiazoles at Low Catalyst Loadings", JOURNAL OF ORGANIC CHEMISTRY, vol. 74, no. 3, 2009, pages 1179 - 1186, XP002596293, Retrieved from the Internet <URL:https://doi.org/10.1021/J0802360D/SUPPL_FILE/JO802360D_SI_001.PDF> DOI: 10.1021/JO802360D
  • - BUCKLEY, D. L.GUSTAFSON, J. L.VAN-MOLLE, I.ROTH, A. G.TAE, H. S.GAREISS, P. C.JORGENSEN, W. L.CIULLI, A.CREWS, C. M.: "Small-Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 51, no. 46, 2012, pages 11463 - 11467, Retrieved from the Internet <URL:https://doi.org/10.1002/ANIE.201206231>
  • - HUBER MAX E. ET AL: "Small Molecule Tools to Study Cellular Target Engagement for the Intracellular Allosteric Binding Site of GPCRs", vol. 29, no. 1, 8 November 2022 (2022-11-08), DE, XP093207447, ISSN: 0947-6539, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/full-xml/10.1002/chem.202202565> DOI: 10.1002/chem.202202565
  • - TOY LARA ET AL: "Fluorescent Ligands Targeting the Intracellular Allosteric Binding Site of the Chemokine Receptor CCR2", vol. 17, no. 8, 15 July 2022 (2022-07-15), pages 2142 - 2152, XP093207521, ISSN: 1554-8929, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/acschembio.2c00263> DOI: 10.1021/acschembio.2c00263
  • - SOSIC IZIDOR ET AL: "E3 ligase ligand chemistries: from building blocks to protein degraders", vol. 51, no. 9, 10 May 2022 (2022-05-10), UK, pages 3487 - 3534, XP093072828, ISSN: 0306-0012, Retrieved from the Internet <URL:https://pubs.rsc.org/en/content/articlepdf/2022/cs/d2cs00148a> DOI: 10.1039/D2CS00148A
  • - TROUP ROBERT I. ET AL: "Current strategies for the design of PROTAC linkers: a critical review", vol. 1, no. 5, 30 October 2020 (2020-10-30), XP055828975, Retrieved from the Internet <URL:https://www.explorationpub.com/uploads/Article/A100218/100218.pdf> DOI: 10.37349/etat.2020.00018
  • - CYRUS K ET AL: "Impact of linker length on the activity of PROTACs", MOLECULAR BIOSYSTEMS, ROYAL SOCIETY OF CHEMISTRY, GB, vol. 7, no. 2, 1 February 2011 (2011-02-01), pages 359 - 364, XP002721196, ISSN: 1742-206X, [retrieved on 20100401], DOI: 10.1039/C0MB00074D
  • - STEINEBACH CHRISTIAN ET AL: "A MedChem toolbox for cereblon-directed PROTACs", MEDCHEMCOMM, vol. 10, no. 6, 19 June 2019 (2019-06-19), United Kingdom, pages 1037 - 1041, XP055857543, ISSN: 2040-2503, DOI: 10.1039/C9MD00185A

Cited patents 14

WO0194341A1 WO0047212A1 WO9722596A1 WO9730035A1 WO9732856A1 WO9813354A1 WO9902166A1 WO0040529A1 WO0041669A2 WO0192224A1 WO0204434A1 WO0208213A1 WO2006076644A2 WO2023031308A1